{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T18:12:10Z","timestamp":1790014330931,"version":"4.0.1"},"reference-count":49,"publisher":"Public Library of Science (PLoS)","issue":"9","license":[{"start":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T00:00:00Z","timestamp":1789948800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100023339","name":"Kidney Cancer UK","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100023339","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000289","name":"Cancer Research UK","doi-asserted-by":"publisher","award":["RCCCTF-Nov21\\100002"],"award-info":[{"award-number":["RCCCTF-Nov21\\100002"]}],"id":[{"id":"10.13039\/501100000289","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS One"],"abstract":"<jats:sec id=\"sec001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>RAMPART is an international phase III trial evaluating adjuvant immune checkpoint inhibitors (ICIs) after nephrectomy for renal cell carcinoma. ICIs have a distinct toxicity profile that can significantly impact health-related quality of life (HRQoL); however existing HRQoL questionnaires were developed in a pre-ICI era and may not fully capture the patient experience. To address this, we embedded a qualitative interview sub-study within RAMPART among UK participants to explore the impact of ICIs on HRQoL in depth.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec002\">\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Eligible participants were enrolled in RAMPART at UK sites and randomised to Arm B (durvalumab q4w for 1 year) or C (durvalumab q4w for 1 year plus tremelimumab at day 1 and week 4). Participants were purposively selected to ensure representation across baseline characteristics, treatment tolerance, toxicity development, and recurrence status. Interviews were conducted online, via telephone and in person, with transcripts analysed using the framework method.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec003\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Of 220 eligible participants, 71 were invited; with recruitment closing early due to a high response rate. 37 expressed interest, and 23 were interviewed. Two themes were generated based on participant insights:\n                      <jats:italic>Living in a Changed Body and Mind<\/jats:italic>\n                      and\n                      <jats:italic>It Depends on Your Life: How Context Shapes the Impact of Immune Related Adverse Events (irAEs)<\/jats:italic>\n                      . The findings suggest that participants often placed greater importance on the duration and chronicity of irAEs than their severity when describing impacts on HRQoL. Persistent toxicities, including fatigue, arthralgia, and diarrhoea, disrupted daily functioning, while cognitive changes and emotional strain were common. Employment, financial security, and caregiving responsibilities influenced the impact of irAEs, whereas supportive relationships and structured follow-up mitigated their burden.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"sec004\">\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Chronic irAEs can negatively affect HRQoL, mental health, and the ability to work. Clinical trials evaluating ICIs should report toxicity grade, duration, and resolution to better inform patient decision-making. Development of ICI-specific HRQoL tools that capture the impact of persistent irAEs is needed, alongside clear care pathways for management of chronic irAEs.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1371\/journal.pone.0358789","type":"journal-article","created":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:41:22Z","timestamp":1790012482000},"page":"e0358789","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":0,"title":["Health-related quality of life with adjuvant immune checkpoint inhibition in renal cell carcinoma: A qualitative study of UK participants in the phase III RAMPART trial"],"prefix":"10.1371","volume":"21","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8080-1948","authenticated-orcid":true,"given":"Sophie","family":"Merrick","sequence":"first","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8912-2001","authenticated-orcid":true,"given":"Annabelle","family":"South","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5978-292X","authenticated-orcid":true,"given":"Elena","family":"Frangou","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah L.","family":"Rush","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]},{"name":"Guy\u2019s and St Thomas\u2019 NHS Foundation Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Grisma","family":"Patel","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1853-3599","authenticated-orcid":true,"given":"Jemima","family":"Thompson","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Plant","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7579-340X","authenticated-orcid":true,"given":"Lisa","family":"Pickering","sequence":"additional","affiliation":[{"name":"The Royal Marsden Hospital NHS Foundation Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ruth E.","family":"Langley","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Duncan C.","family":"Gilbert","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Powles","sequence":"additional","affiliation":[{"name":"St Bartholomew\u2019s Hospital","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5569-9523","authenticated-orcid":true,"given":"James","family":"Larkin","sequence":"additional","affiliation":[{"name":"The Royal Marsden Hospital NHS Foundation Trust","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Meade","sequence":"additional","affiliation":[{"name":"UCL Innovative Clinical Trials Unit, Institute of Clinical Trials and Methodology, UCL","place":["London, United Kingdom"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2026,9,21]]},"reference":[{"issue":"10451","key":"pone.0358789.ref001","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(24)00917-6","article-title":"Renal cell carcinoma","volume":"404","author":"M Young","year":"2024","journal-title":"Lancet"},{"issue":"15","key":"pone.0358789.ref002","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1056\/NEJMoa2312695","article-title":"Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma","volume":"390","author":"TK Choueiri","year":"2024","journal-title":"N Engl J Med"},{"issue":"8","key":"pone.0358789.ref003","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1056\/NEJMoa2106391","article-title":"Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma","volume":"385","author":"TK Choueiri","year":"2021","journal-title":"N Engl J Med"},{"issue":"10358","key":"pone.0358789.ref004","doi-asserted-by":"crossref","first-page":"1103","DOI":"10.1016\/S0140-6736(22)01658-0","article-title":"Adjuvant atezolizumab versus placebo for patients with renal cell carcinoma at increased risk of recurrence following resection (IMmotion010): a multicentre, randomised, double-blind, phase 3 trial","volume":"400","author":"SK Pal","year":"2022","journal-title":"Lancet"},{"issue":"2","key":"pone.0358789.ref005","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1200\/JCO.24.00773","article-title":"Adjuvant Nivolumab for Localized Renal Cell Carcinoma at High Risk of Recurrence After Nephrectomy: Part B of the Randomized, Placebo-Controlled, Phase III CheckMate 914 Trial","volume":"43","author":"RJ Motzer","year":"2025","journal-title":"J Clin Oncol"},{"issue":"10379","key":"pone.0358789.ref006","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1016\/S0140-6736(22)02574-0","article-title":"Adjuvant nivolumab plus ipilimumab versus placebo for localised renal cell carcinoma after nephrectomy (CheckMate 914): a double-blind, randomised, phase 3 trial","volume":"401","author":"RJ Motzer","year":"2023","journal-title":"Lancet"},{"key":"pone.0358789.ref007","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.TPS4596","article-title":"PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143)","volume":"39","author":"ME Allaf","year":"2021","journal-title":"J Clin Oncol"},{"key":"pone.0358789.ref008","doi-asserted-by":"crossref","DOI":"10.1016\/j.annonc.2025.09.110","article-title":"First results from RAMPART: An international phase III randomised-controlled trial of adjuvant durvalumab monotherapy or combined with tremelimumab for resected primary renal cell carcinoma (RCC) led by MRC CTU at UCL","volume":"36","author":"J Larkin","year":"2025","journal-title":"Ann Oncol"},{"issue":"2","key":"pone.0358789.ref009","doi-asserted-by":"crossref","DOI":"10.1016\/S1470-2045(24)00451-0","article-title":"Common Sense Oncology principles for the design, analysis, and reporting of phase 3 randomised clinical trials","volume":"26","author":"B Gyawali","year":"2025","journal-title":"Lancet Oncol"},{"issue":"8","key":"pone.0358789.ref010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/S1470-2045(23)00319-4","article-title":"Common Sense Oncology: outcomes that matter","volume":"24","author":"CM Booth","year":"2023","journal-title":"Lancet Oncol"},{"issue":"7","key":"pone.0358789.ref011","doi-asserted-by":"crossref","first-page":"917","DOI":"10.1016\/j.annonc.2021.03.204","article-title":"Delayed immune-related adverse events with anti-PD-1-based immunotherapy in melanoma","volume":"32","author":"CN Owen","year":"2021","journal-title":"Ann Oncol"},{"issue":"8","key":"pone.0358789.ref012","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.27145","article-title":"Extended Follow-Up of Chronic Immune-Related Adverse Events Following Adjuvant Anti-PD-1 Therapy for High-Risk Resected Melanoma","volume":"6","author":"RS Goodman","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"4","key":"pone.0358789.ref013","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1038\/s41571-022-00600-w","article-title":"Immune-checkpoint inhibitors: long-term implications of toxicity","volume":"19","author":"DB Johnson","year":"2022","journal-title":"Nat Rev Clin Oncol"},{"key":"pone.0358789.ref014","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/j.ejca.2020.04.025","article-title":"Late immune-related adverse events in long-term responders to PD-1\/PD-L1 checkpoint inhibitors: A multicentre study","volume":"134","author":"O Nigro","year":"2020","journal-title":"Eur J Cancer"},{"key":"pone.0358789.ref015","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1016\/j.ejca.2021.03.010","article-title":"Late-onset and long-lasting immune-related adverse events from immune checkpoint-inhibitors: An overlooked aspect in immunotherapy","volume":"149","author":"E Ghisoni","year":"2021","journal-title":"Eur J Cancer"},{"issue":"10","key":"pone.0358789.ref016","doi-asserted-by":"crossref","first-page":"2377","DOI":"10.1093\/annonc\/mdx286","article-title":"Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review","volume":"28","author":"L Khoja","year":"2017","journal-title":"Ann Oncol"},{"key":"pone.0358789.ref017","doi-asserted-by":"crossref","first-page":"102536","DOI":"10.1016\/j.eclinm.2024.102536","article-title":"Clinical spectrum and evolution of immune-checkpoint inhibitors toxicities over a decade-a worldwide perspective","volume":"70","author":"P Gougis","year":"2024","journal-title":"EClinicalMedicine"},{"key":"pone.0358789.ref018","unstructured":"meeting-report-ema-eortc-workshop-how-can-patient-reported-outcomes-pro-health-related-quality-life-hrqol-data-inform-regulatory-decisions_en_pdf"},{"key":"pone.0358789.ref019","doi-asserted-by":"crossref","first-page":"102862","DOI":"10.1016\/j.ctrv.2024.102862","article-title":"Identification of the PROMs used to assess ICI toxicities and HRQoL in patients receiving immune checkpoint inhibitor treatment in cancer care and their suitability: A systematic review","volume":"135","author":"S Georgopoulou","year":"2025","journal-title":"Cancer Treat Rev"},{"issue":"1","key":"pone.0358789.ref020","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1016\/j.euo.2024.09.007","article-title":"Health-related Quality of Life Assessment in Renal Cell Cancer: A Scoping Review","volume":"8","author":"F Gross","year":"2025","journal-title":"Eur Urol Oncol"},{"issue":"1","key":"pone.0358789.ref021","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0227344","article-title":"Health-related quality of life in cancer patients treated with immune checkpoint inhibitors: A systematic review on reporting of methods in randomized controlled trials","volume":"15","author":"S Faury","year":"2020","journal-title":"PLoS One"},{"issue":"1","key":"pone.0358789.ref022","doi-asserted-by":"crossref","first-page":"58","DOI":"10.1186\/s41687-020-00210-z","article-title":"Patient-reported outcome instruments used in immune-checkpoint inhibitor clinical trials in oncology: a systematic review","volume":"4","author":"S Colomer-Lahiguera","year":"2020","journal-title":"J Patient Rep Outcomes"},{"key":"pone.0358789.ref023","volume-title":"Successful Qualitative Research: a practical guide for beginners","author":"V Braun","year":"2013","edition":"1"},{"issue":"6","key":"pone.0358789.ref024","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1093\/intqhc\/mzm042","article-title":"Consolidated criteria for reporting qualitative research (COREQ): a 32-item checklist for interviews and focus groups","volume":"19","author":"A Tong","year":"2007","journal-title":"Int J Qual Health Care"},{"issue":"13","key":"pone.0358789.ref025","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.1177\/1049732315617444","article-title":"Sample Size in Qualitative Interview Studies: Guided by Information Power","volume":"26","author":"K Malterud","year":"2016","journal-title":"Qual Health Res"},{"key":"pone.0358789.ref026","article-title":"Using Framework Analysis in Applied Qualitative Research","author":"L Goldsmith","year":"2021","journal-title":"Qual Rep"},{"key":"pone.0358789.ref027","volume-title":"Qualitative research practice: A guide for social science students and researchers, Second edition","author":"J Ritchie","year":"2013"},{"key":"pone.0358789.ref028","unstructured":"NVivo NVivo 14 Windows. https:\/\/techcenter.qsrinternational.com\/Content\/nv14\/nv14_standard_installation.htm Accessed 13 Aug 2025."},{"issue":"3","key":"pone.0358789.ref029","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2022-006398","article-title":"Society for Immunotherapy of Cancer (SITC) consensus definitions for immune checkpoint inhibitor-associated immune-related adverse events (irAEs) terminology","volume":"11","author":"J Naidoo","year":"2023","journal-title":"J Immunother Cancer"},{"issue":"1","key":"pone.0358789.ref030","doi-asserted-by":"crossref","first-page":"1128","DOI":"10.1186\/s12885-020-07518-5","article-title":"The quality of reporting general safety parameters and immune-related adverse events in clinical trials of FDA-approved immune checkpoint inhibitors","volume":"20","author":"Z Karimian","year":"2020","journal-title":"BMC Cancer"},{"issue":"3","key":"pone.0358789.ref031","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S1470-2045(17)30015-3","article-title":"Health-related quality of life with adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): secondary outcomes of a multinational, randomised, double-blind, phase 3 trial","volume":"18","author":"C Coens","year":"2017","journal-title":"Lancet Oncol"},{"key":"pone.0358789.ref032","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ejca.2017.05.031","article-title":"Health-related quality of life results from the phase III CheckMate 067 study","volume":"82","author":"D Schadendorf","year":"2017","journal-title":"Eur J Cancer"},{"key":"pone.0358789.ref033","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.ejca.2023.02.005","article-title":"Impact of immune checkpoint inhibitors and targeted therapy on health-related quality of life of people with stage III and IV melanoma: a mixed-methods systematic review","volume":"184","author":"J Lai-Kwon","year":"2023","journal-title":"Eur J Cancer"},{"issue":"3","key":"pone.0358789.ref034","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1007\/s11764-023-01507-w","article-title":"Survivorship outcomes in patients treated with immune checkpoint inhibitors: a scoping review","volume":"19","author":"DC G\u00fcven","year":"2025","journal-title":"J Cancer Surviv"},{"key":"pone.0358789.ref035","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.ejca.2022.08.029","article-title":"Persistent immune-related adverse events after cessation of checkpoint inhibitor therapy: Prevalence and impact on patients\u2019 health-related quality of life","volume":"176","author":"TU Schulz","year":"2022","journal-title":"Eur J Cancer"},{"key":"pone.0358789.ref036","article-title":"3191eP Development of an EORTC strategy to measure health-related quality of life in cancer patients receiving immune checkpoint inhibitors: Phase I and II","volume":"36","author":"L Fox","year":"2025","journal-title":"Ann Oncol"},{"key":"pone.0358789.ref037","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1200\/JCO.2025.43.5_suppl.526","article-title":"Development of a FKSI-23: A new bespoke health-related quality of life (HRQOL) questionnaire for the advanced and adjuvant setting in renal cell carcinoma (RCC)","volume":"43","author":"CD Bergerot","year":"2025","journal-title":"J Clin Oncol"},{"key":"pone.0358789.ref038","unstructured":"EORTC Quality of Life Group (2021) Renal Cancer. https:\/\/qol.eortc.org\/questionnaire\/renal-cancer\/ Accessed 14 Nov 2025."},{"issue":"1","key":"pone.0358789.ref039","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1080\/0284186X.2020.1818823","article-title":"Health-related quality of life of long-term advanced melanoma survivors treated with anti-CTLA-4 immune checkpoint inhibition compared to matched controls","volume":"60","author":"AH Boekhout","year":"2021","journal-title":"Acta Oncol"},{"issue":"4","key":"pone.0358789.ref040","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1007\/s11136-008-9333-6","article-title":"Listen to their answers! Response behaviour in the measurement of physical and role functioning","volume":"17","author":"MJ Westerman","year":"2008","journal-title":"Qual Life Res"},{"issue":"2","key":"pone.0358789.ref041","article-title":"Response shift effects of quality of life assessments in breast cancer survivors","volume":"28","author":"M Friedrich","year":"2019","journal-title":"Eur J Cancer Care (Engl)"},{"key":"pone.0358789.ref042","doi-asserted-by":"crossref","first-page":"113601","DOI":"10.1016\/j.ejca.2024.113601","article-title":"Real-world health-related quality of life outcomes for patients with resected stage III\/IV melanoma treated with adjuvant anti-PD1 therapy","volume":"200","author":"M Egeler","year":"2024","journal-title":"Eur J Cancer"},{"key":"pone.0358789.ref043","doi-asserted-by":"crossref","first-page":"2192480","DOI":"10.1155\/2020\/2192480","article-title":"Neurocognitive Function, Psychosocial Outcome, and Health-Related Quality of Life of the First-Generation Metastatic Melanoma Survivors Treated with Ipilimumab","volume":"2020","author":"A Rogiers","year":"2020","journal-title":"J Immunol Res"},{"issue":"7","key":"pone.0358789.ref044","first-page":"3267","article-title":"Health-related quality of life, emotional burden, and neurocognitive function in the first generation of metastatic melanoma survivors treated with pembrolizumab: a longitudinal pilot study","volume":"28","author":"A Rogiers","year":"2020","journal-title":"Support Care Cancer"},{"issue":"1","key":"pone.0358789.ref045","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2019-000260","article-title":"Quality of life in long-term survivors of advanced melanoma treated with checkpoint inhibitors","volume":"8","author":"M Mamoor","year":"2020","journal-title":"J Immunother Cancer"},{"issue":"6","key":"pone.0358789.ref046","doi-asserted-by":"crossref","first-page":"928","DOI":"10.3390\/cancers17060928","article-title":"Immune Checkpoint Inhibitors and Cognition in Adults with Cancer: A Scoping Review","volume":"17","author":"S Hearne","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"9","key":"pone.0358789.ref047","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.3390\/cancers16091638","article-title":"Emotional Distress, Cognitive Complaints, and Care Needs among Advanced Cancer Survivors Treated with Immune Checkpoint Blockade: A Mixed-Method Study","volume":"16","author":"N Vanlaer","year":"2024","journal-title":"Cancers (Basel)"},{"issue":"1","key":"pone.0358789.ref048","doi-asserted-by":"crossref","first-page":"1599","DOI":"10.1186\/s12885-025-15069-w","article-title":"Health-related quality of life and symptom burden in patients with melanoma during and after immune checkpoint inhibitor therapy - a pilot study","volume":"25","author":"L P\u00f6schmann","year":"2025","journal-title":"BMC Cancer"},{"issue":"2","key":"pone.0358789.ref049","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1080\/07347332.2020.1836547","article-title":"The experience of financial toxicity among advanced melanoma patients treated with immunotherapy","volume":"39","author":"B Thom","year":"2021","journal-title":"J Psychosoc Oncol"}],"container-title":["PLOS One"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358789","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T17:41:34Z","timestamp":1790012494000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0358789"}},"subtitle":[],"editor":[{"given":"Alireza","family":"Shoari","sequence":"first","affiliation":[{"name":"Mayo Clinic Cancer Center","place":["UNITED STATES OF AMERICA"]}],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2026,9,21]]},"references-count":49,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2026,9,21]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0358789","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,21]]}}}